A2A-adenosine receptor reserve for coronary vasodilation. 1998

J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
Department of Medicine, University of Florida, Gainesville 32610, USA.

BACKGROUND Adenosine is a potent coronary vasodilator and causes an increase of coronary blood flow by activation of A2A-adenosine receptors (A2A-AdoRs). The purpose of this study was to test the hypothesis that the high potency of adenosine and adenosine analogues to cause coronary vasodilation is explained by the presence of a large A2A-AdoR reserve ("spare receptors"). RESULTS A novel, irreversible antagonist of A2A-AdoRs was used to inactivate receptors and reduce the response to agonist. Agonist-induced increases of coronary conductance before and after exposure of hearts to the irreversible antagonist were compared. Three agonists were studied: 2-p-(2-carboxyethyl)-phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS21680), adenosine, and 2-chloro-N6-cyclopentyladenosine (CCPA). Data were analyzed to determine agonist KA (equilibrium dissociation constant) and EC50 values. Values of KA for activation of A2A-AdoRs by CGS21680, adenosine, and CCPA were 105, 1800, and 2630 nmol/L, respectively. In contrast, values of EC50 for CGS21680, adenosine, and CCPA to increase coronary conductance were 1.5, 85, and 243 nmol/L, respectively. By use of the law of mass action, it was calculated that half-maximal responses to CGS21680, adenosine, and CCPA occurred when only 1.3%, 5%, and 9%, respectively, of A2A-AdoRs were occupied by agonist. CONCLUSIONS Receptor reserves for 3 A2A-AdoR agonists were large. The receptor reserve for A2A-AdoRs to cause an increase of coronary conductance can explain both the high potency of adenosine to cause coronary vasodilation and the observation that an A2A-AdoR agonist can cause coronary vasodilation without systemic effects.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D005260 Female Females
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
July 2001, The Journal of pharmacology and experimental therapeutics,
J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
October 2020, Heart and vessels,
J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
January 2015, Kidney international,
J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
January 2003, Journal of cardiovascular pharmacology,
J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
April 2018, Journal of the American Heart Association,
J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
November 2020, Journal of medicinal chemistry,
J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
January 2010, Basic research in cardiology,
J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
January 2001, Farmaco (Societa chimica italiana : 1989),
J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
January 2023, International review of neurobiology,
J C Shryock, and S Snowdy, and P G Baraldi, and B Cacciari, and G Spalluto, and A Monopoli, and E Ongini, and S P Baker, and L Belardinelli
January 1993, Advances in experimental medicine and biology,
Copied contents to your clipboard!